Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib Combined With Sintilimab for Advanced HCC
NCT05162352Phase 2Completed
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib, sintilimab in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Dec 2021; status: completed.
02
Drugs
donafenibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05162352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162352.